New drug combo targets Hard-to-Treat breast cancer
NCT ID NCT03742245
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety of combining two drugs, olaparib and vorinostat, in people with advanced breast cancer that has returned or spread. About 28 participants will receive the combination to find the best dose and check for side effects. The goal is to see if this approach can help control the disease when other treatments have stopped working.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?